

AlzeCure Pharma carries out a directed share issue in follow-up to a previously given subscription commitment

AlzeCure Pharma AB (“AlzeCure” or the “Company”) carried out a new issue of shares in the spring of 2024 with observance of the shareholders' preferential subscription rights (the “Rights Issue”). The Company's shareholder FV Group AB had undertaken to subscribe for its pro rata share of the shares in the Rights Issue, corresponding to SEK 3,740,000. Only later have FV Group AB and the Company been able to ascertain that, due to a mistake, subscription never took place. FV Group AB is now instead subscribing for what FV Group AB would have subscribed for in the Rights Issue in accordance with its previous commitment.

Background

The Rights Issue was approved by the Extraordinary General Meeting on April 25, 2024 and then closed on May 17, 2024. The outcome was reported in a press release on May 20, 2024. Already in March, FV Group AB had undertaken to subscribe for its pro rata share, at the time approximately 7.1 percent, of the shares in the then upcoming Rights Issue, corresponding to 2,200,000 shares. FV Group AB's subscription commitment is reported in the prospectus that the Company prepared in connection with the Rights Issue.

During the month of July, the Company and FV Group AB have jointly been able to establish that FV Group AB's subscription in accordance with the agreement never took place. FV Group AB has explained that the company's belief was that it fulfilled its subscription commitment under the Rights Issue.

For AlzeCure, it is important to secure the capital contribution that FV Group AB has undertaken to provide with its subscription commitment - a subscription commitment that has also been reported to the market and thus could form the basis for others' investment decisions in the Rights Issue. There are thus reasons to, with deviation from the shareholders' preferential rights, now decide on the issue of the shares that FV Group AB would have subscribed for in the Rights Issue.

The subscription price per share under the subscription undertaking would correspond to the subscription price per share in the Rights Issue, i.e. SEK 1.70 per share. The subscription price had been determined in discussions with those who eventually came to issue guarantees and subscription commitments in the Rights Issue, and after the Company's assessment of what price was otherwise required for a successful completion of the Rights Issue.

Directed new share issue

In light of the above, the Company's board of directors has today, based on the authorization granted at the Annual General Meeting on 14 May 2024, resolved on a new issue of a maximum of 2,200,000 shares in the Company to, with deviation from the shareholders' preferential rights, be subscribed for by FV Group AB at a subscription price of SEK 1.70 per share, in total corresponding to SEK 3,740,000, in accordance with FV Group AB's previously made commitment.

With the new share issue, the Company's number of outstanding shares will increase from 86,095,200 to a total of 88,295,200 and the Company's share capital from SEK 2,152,380 to a total of SEK 2,207,380.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se

This information is information that AlzeCure Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-18 09:00 CEST.

Attachments

AlzeCure Pharma carries out a directed share issue in follow-up to a previously given subscription commitment